Raymond James Financial Services Advisors’s Cyclacel Pharmaceuticals CYCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-6
| Closed | -$7.38K | – | 3312 |
|
|
2023
Q3 | $7.38K | Hold |
6
| – | – | ﹤0.01% | 3215 |
|
|
2023
Q2 | $12.3K | Hold |
6
| – | – | ﹤0.01% | 3194 |
|
|
2023
Q1 | $11.9K | Hold |
6
| – | – | ﹤0.01% | 3203 |
|
|
2022
Q4 | $13.9K | Hold |
6
| – | – | ﹤0.01% | 3155 |
|
|
2022
Q3 | $30K | Sell |
6
-3
| -33% | -$15K | ﹤0.01% | 3119 |
|
|
2022
Q2 | $33K | Buy |
9
+6
| +200% | +$22K | ﹤0.01% | 3099 |
|
|
2022
Q1 | $31K | Hold |
3
| – | – | ﹤0.01% | 3194 |
|
|
2021
Q4 | $43K | Hold |
3
| – | – | ﹤0.01% | 3180 |
|
|
2021
Q3 | $53K | Sell |
3
-14
| -82% | -$247K | ﹤0.01% | 3168 |
|
|
2021
Q2 | $355K | Hold |
17
| – | – | ﹤0.01% | 2603 |
|
|
2021
Q1 | $441K | Buy |
17
+1
| +6% | +$25.9K | ﹤0.01% | 2372 |
|
|
2020
Q4 | $445K | Buy |
16
+3
| +23% | +$83.4K | ﹤0.01% | 2215 |
|
|
2020
Q3 | $167K | Buy |
13
+4
| +44% | +$51.4K | ﹤0.01% | 2578 |
|
|
2020
Q2 | $143K | Buy |
9
+8
| +800% | +$127K | ﹤0.01% | 2561 |
|
|
2020
Q1 | $23K | Hold |
1
| – | – | ﹤0.01% | 2343 |
|
|
2019
Q4 | $40K | Hold |
1
| – | – | ﹤0.01% | 2762 |
|
|
2019
Q3 | $30K | Hold |
1
| – | – | ﹤0.01% | 2712 |
|
|
2019
Q2 | $41K | Hold |
1
| – | – | ﹤0.01% | 2743 |
|
|
2019
Q1 | $70K | Hold |
1
| – | – | ﹤0.01% | 2668 |
|
|
2018
Q4 | $30K | Hold |
1
| – | – | ﹤0.01% | 2486 |
|
|
2018
Q3 | $69K | Hold |
1
| – | – | ﹤0.01% | 2688 |
|
|
2018
Q2 | $57K | Buy |
+1
| New | +$57K | ﹤0.01% | 2655 |
|
|
2018
Q1 | – | Hold |
0
| – | -$52K | – | 2443 |
|
|
2017
Q4 | – | Hold |
0
| – | -$37K | – | 2419 |
|
|
2017
Q3 | – | Hold |
0
| – | -$38K | – | 2454 |
|
|
2017
Q2 | – | Hold |
0
| – | -$59K | – | 2410 |
|
|
2017
Q1 | – | Hold |
0
| – | -$58K | – | 2293 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 2216 |
|